icon-folder.gif   Conference Reports for NATAP  
 
  The Liver Meeting
Digital Experience
AASLD
November 13 - 16 - 2020
Back grey_arrow_rt.gif
 
 
 
Short-term therapy with GSK3228836 in chronic hepatitis B (CHB) patients results in reductions in HBcrAg and HBV RNA: Phase 2a, randomized, double-blind, placebo-controlled study
 
 
  AASLD 2020 Nov 11-16
Reported by Jules Levin
 
Shihyun You1, Phillip Yates2, Rob Elston2, Yu Tao1, 13 Melanie Paff , Dickens Theodore 1GSK, Collegeville, PA, USA; 2GSK, Stevenage, Hertfordshire, UK; 3GSK, Research Triangle Park, NC, USA

1123201

1123202

1123203

1123204

1123205

1123206

1123207